论文部分内容阅读
[目的]观察匹维溴胺对腹泻型肠易激综合征(IBS-D)模型大鼠结肠组织血管活性肠肽(VIP)水平及其受体1(VIP-R1)表达变化,探讨匹维溴胺治疗IBS-D机制。[方法]采用应激与束缚相结合的方法复制IBS-D模型后,应用ELISA、免疫组化、逆转录聚合酶链反应(RT-PCR)检测结肠组织VIP水平及VIP-R1的表达。[结果]匹维溴胺组结肠组织中VIP及其VIP-R1 mRNA的表达均明显低于模型组和对照组(均P<0.05)。[结论]匹维溴胺治疗IBS-D模型大鼠的药理学作用与VIP水平及VIP-R1表达下调有关。
[Objective] To observe the changes of vasoactive intestinal peptide (VIP) and its receptor 1 (VIP-R1) in the colon of diarrhea-predominant irritable bowel syndrome (IBS-D) Bromine treatment of IBS-D mechanism. [Method] After IBS-D model was duplicated by binding stress and restraint, the VIP level and the expression of VIP-R1 in colonic tissue were detected by ELISA, immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR). [Results] The VIP and VIP-R1 mRNA expressions in the colon of Pivobromide group were significantly lower than those in the model group and the control group (all P <0.05). [Conclusion] The pharmacological effects of pirfenirol in IBS-D model rats are related to the decrease of VIP level and VIP-R1 expression.